MCID: KRT006
MIFTS: 54

Keratoconjunctivitis

Categories: Eye diseases, Infectious diseases

Aliases & Classifications for Keratoconjunctivitis

Summaries for Keratoconjunctivitis

MalaCards based summary : Keratoconjunctivitis is related to vernal keratoconjunctivitis and keratoconjunctivitis sicca. An important gene associated with Keratoconjunctivitis is RNASE3 (Ribonuclease A Family Member 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Tacrolimus and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and t cells, and related phenotypes are hematopoietic system and digestive/alimentary

Wikipedia : 76 Keratoconjunctivitis is inflammation ("-itis") of the cornea and... more...

Related Diseases for Keratoconjunctivitis

Diseases related to Keratoconjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 378)
# Related Disease Score Top Affiliating Genes
1 vernal keratoconjunctivitis 33.8 CCL11 ICAM1 IL13 IL4 IL5 RNASE3
2 keratoconjunctivitis sicca 33.7 IL4 NGF TLR9 TNF
3 atopic keratoconjunctivitis 33.4 IFNG IL2 IL3 IL4 IL5 RNASE3
4 dry eye syndrome 32.1 NGF TLR9 TNF
5 graft-versus-host disease 30.4 IFNG IL2 TNF
6 chlamydia 30.1 CXCL8 IFNG IL4 TNF
7 uveitis 30.1 ICAM1 IFNG IL4 TNF
8 papillary conjunctivitis 30.1 CCL11 CXCL8 IL4
9 cellulitis 29.9 IL5 RNASE3 TNF
10 lichen planus 29.9 ICAM1 IFNG IL4 TLR9 TNF
11 neuritis 29.9 IFNG IL4 TNF
12 conjunctivitis 29.9 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
13 acquired immunodeficiency syndrome 29.9 IFNG IL2 TNF
14 ocular cicatricial pemphigoid 29.9 IL4 NGF RNASE3
15 giant papillary conjunctivitis 29.8 CCL11 CXCL8 IL4 RNASE3
16 rheumatoid arthritis 29.8 CXCL8 ICAM1 IFNG IL2 IL4 TNF
17 allergic conjunctivitis 29.7 CCL11 CXCL8 ICAM1 IFNG IL13 IL4
18 human immunodeficiency virus type 1 29.7 CCL11 IFNG IL2 TNF
19 sleep apnea 29.7 CXCL8 ICAM1 TNF
20 peritonitis 29.7 CXCL8 ICAM1 TNF
21 dermatitis 29.7 CCL11 CCL17 IFNG IL13 IL4 IL5
22 sinusitis 29.6 CXCL8 IL5 RNASE3
23 alopecia areata 29.6 ICAM1 IFNG IL2 TNF
24 erythema multiforme 29.4 CCL17 ICAM1 IFNG IL2 TNF
25 otitis media 29.4 CCL11 CXCL8 IL4 RNASE3 TNF
26 viral infectious disease 29.4 CXCL8 IFNG IL2 IL4 TLR9 TNF
27 colitis 29.4 CXCL8 IFNG IL2 IL4 TLR9 TNF
28 pleurisy 29.4 CXCL8 ICAM1 IFNG IL2 TNF
29 autoimmune disease 29.4 IFNG IL2 IL4 IL5 TLR9 TNF
30 common variable immunodeficiency 29.3 IFNG IL2 IL4 IL5 TLR9 TNF
31 allergic asthma 29.0 CCL11 CCL17 IFNG IL13 IL4 IL5
32 allergic rhinitis 29.0 CCL11 CXCL8 ICAM1 IFNG IL13 IL4
33 rhinitis 28.9 CCL11 CXCL8 ICAM1 IL13 IL4 IL5
34 contact dermatitis 28.8 CCL17 CXCL8 ICAM1 IFNG IL4 IL5
35 dermatitis, atopic 28.2 CCL11 CCL17 CXCL8 ICAM1 IFNG IL13
36 asthma 27.9 CCL11 CCL17 CXCL8 ICAM1 IFNG IL13
37 superior limbic keratoconjunctivitis 12.6
38 punctate epithelial keratoconjunctivitis 12.2
39 neurotrophic keratoconjunctivitis 12.0
40 sjogren syndrome 11.9
41 phlyctenulosis 11.9
42 shipyard eye 11.9
43 acute contagious conjunctivitis 11.4
44 exposure keratitis 11.2
45 myelopathy, htlv-1-associated 11.0
46 aplasia of lacrimal and salivary glands 11.0
47 tropical spastic paraparesis 11.0
48 retrovirus-associated myelopathy 11.0
49 egg allergy 10.3 IL4 IL5
50 loeffler endocarditis 10.3 IL5 RNASE3

Comorbidity relations with Keratoconjunctivitis via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Keratoconjunctivitis:



Diseases related to Keratoconjunctivitis

Symptoms & Phenotypes for Keratoconjunctivitis

MGI Mouse Phenotypes related to Keratoconjunctivitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 AOC1 CCL11 CCL17 ICAM1 IFNG IL13
2 digestive/alimentary MP:0005381 9.92 ICAM1 IFNG IL13 IL2 IL4 IL5
3 immune system MP:0005387 9.85 CCL11 CCL17 ICAM1 IFNG IL13 IL2
4 respiratory system MP:0005388 9.5 CCL11 IFNG IL13 IL2 IL4 IL5
5 vision/eye MP:0005391 9.23 AOC1 CD46 ICAM1 IFNG IL2 IL4

Drugs & Therapeutics for Keratoconjunctivitis

Drugs for Keratoconjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 256)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 104987-11-3 445643 439492
2
Tocopherol Approved, Investigational Phase 4,Not Applicable 1406-66-2 14986
3
Povidone Approved Phase 4,Not Applicable 9003-39-8
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
5
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9004-61-9 53477741
6
Loteprednol Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 82034-46-6, 129260-79-3 9865442 444025
7
Tobramycin Approved, Investigational Phase 4,Not Applicable 32986-56-4 36294 5496
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-02-2 5743
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1177-87-3
10
Iodine Approved, Investigational Phase 4,Not Applicable 7553-56-2 807
11
Glycerol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 56-81-5 753
12
Histamine Approved, Investigational Phase 4,Phase 3 51-45-6, 75614-87-8 774
13
Povidone-iodine Approved Phase 4 25655-41-8
14
Ganciclovir Approved, Investigational Phase 4,Phase 2,Not Applicable 82410-32-0 3454
15 Lifitegrast Approved Phase 4,Phase 3,Phase 2,Not Applicable 1025967-78-5
16
Menthol Approved Phase 4 2216-51-5 16666
17
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6
18
Ethanol Approved Phase 4,Not Applicable 64-17-5 702
19
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
20
Dimenhydrinate Approved Phase 4,Not Applicable 523-87-5 441281
21
Azithromycin Approved Phase 4 83905-01-5 55185 447043
22
Ketorolac Approved Phase 4,Phase 2 66635-83-4, 74103-06-3 3826
23
Dipivefrin Approved Phase 4,Phase 1 52365-63-6 3105
24
Ofloxacin Approved Phase 4 82419-36-1 4583
25
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
26
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3 302-25-0
27
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
28
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3 2921-57-5
29
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
30
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 564-25-0 54671203
31
Sorbitol Approved Phase 4 50-70-4 5780
32
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 59-02-9 14985
33
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 1406-16-2
34
Vitamin D3 Approved, Nutraceutical Phase 4,Not Applicable 67-97-0 5280795 6221
35
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 11103-57-4, 68-26-8 445354
36
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Not Applicable 8001-79-4
37
Glutamic Acid Approved, Nutraceutical Phase 4 56-86-0 33032
38
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795
39 Tocotrienol Investigational Phase 4,Not Applicable 6829-55-6
40
Bromfenac Approved July 1997 Phase 4,Phase 3,Phase 2 91714-94-2 60726
41
Prednisolone hemisuccinate Experimental Phase 4,Phase 3 2920-86-7
42 Rebamipide Investigational Phase 4,Phase 3,Phase 2,Phase 1 90098-04-7
43 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Omega 3 Fatty Acid Phase 4,Phase 2,Phase 3,Not Applicable
49 Tocotrienols Phase 4,Not Applicable
50 Micronutrients Phase 4,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 533)
# Name Status NCT ID Phase Drugs
1 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
2 Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity Unknown status NCT02992535 Phase 4
3 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
4 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
5 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
6 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
7 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
8 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
9 A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis Completed NCT03464435 Phase 4 Tacrolimus
10 Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
11 Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis Completed NCT00357019 Phase 4 N-acetyl-aspartyl-glutamate (NAAXIA Sine)
12 Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Completed NCT01179412 Phase 4 2% povidone-iodine;2% povidone-iodine
13 A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Completed NCT02139033 Phase 4 Retaine™
14 A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis Completed NCT01533480 Phase 4 Zirgan;genteal gel
15 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
16 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
17 Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed NCT00407043 Phase 4 Lotemax;Restasis
18 Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness Completed NCT03686878 Phase 4 Lifitegrast
19 Comparative Study of Rohto Dry-Aid® and Systane® Ultra in Patients With Dry Eye Completed NCT03183089 Phase 4 Rohto Dry-Aid®;Systane® Ultra
20 Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra) Completed NCT02985827 Phase 4 Rohto (r) Hydra;Systane (r) Ultra
21 A Study of the Effect of Zinc-Hyaluronate on Ocular Surface Sensations in Patients With Dry Eye Completed NCT02951910 Phase 4
22 Comparison of Autologous Serum Versus Preservative Free Artificial Tear Completed NCT02752763 Phase 4 %40 diluted Autologous serum;Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)
23 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN) Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
24 Tear Lipid Layer Thickness With Emollient Eye Drops Completed NCT03380624 Phase 4 Refresh Optive;Refresh Optimum OMEGA 3
25 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Completed NCT01684436 Phase 4
26 Efficacy Study of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4
27 Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops Completed NCT02758327 Phase 4 TheraTears Lubricating Eye Drops
28 Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis® Completed NCT02554981 Phase 4 Cyclosporine 0.05% Ophthalmic Emulsion
29 Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye Completed NCT01105910 Phase 4
30 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE) Completed NCT01105624 Phase 4 azithromycin ophthalmic solution, 1%;Visine® for Contacts®
31 Efficacy of Systane Balance to Stabilize the Tear Film in Dry Eye Subjects Completed NCT01086774 Phase 4
32 A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens Completed NCT01061268 Phase 4 No topical artificial tear;Blink® Tears Lubricant Eye Drops
33 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms Completed NCT00938704 Phase 4 carboxymethylcellulose 0.5% +glycerin 0.9%;sodium hyaluronate 0.18%
34 Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy Completed NCT02121847 Phase 4 cyclosporine 0.05% ophthalmic emulsion;carboxymethylcellulose-based lubricant eye drops
35 Kynex Versus Refresh Plus Study in Subject With Dry Eye Completed NCT00809198 Phase 4
36 A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes Completed NCT00781092 Phase 4
37 Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects Completed NCT01970917 Phase 4
38 Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms Completed NCT00761202 Phase 4 A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®;Sodium hyaluronate
39 Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye Completed NCT00724412 Phase 4
40 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality Completed NCT00622037 Phase 4 PEG-400 based artificial tear;Systane
41 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK). Completed NCT00620893 Phase 4 PEG- 400 based artificial tear;Systane
42 Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes Completed NCT00469573 Phase 4 1. Optive
43 Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00405457 Phase 4 Restasis, Optive Tears
44 A Comparison of Optive in Patients Previously Using Systane for the Treatment of Dry Eye Completed NCT00399230 Phase 4 Optive
45 Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00399061 Phase 4 Systane, Optive, Restasis
46 Comparison of Systane Free vs. Saline in the Treatment of Dry Eye Completed NCT00388791 Phase 4 Systane Free
47 Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Completed NCT00386646 Phase 4 0.5% carboxymethylcellulose (CMC) with purite and CMC alone
48 Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Completed NCT00349440 Phase 4 Cyclosporine, Refresh Plus
49 The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients Completed NCT01280110 Phase 4 Hydroxypropylmethylcellulose;Carboxymethylcellulose
50 Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Completed NCT01198782 Phase 4

Search NIH Clinical Center for Keratoconjunctivitis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: keratoconjunctivitis

Genetic Tests for Keratoconjunctivitis

Anatomical Context for Keratoconjunctivitis

MalaCards organs/tissues related to Keratoconjunctivitis:

41
Eye, Testes, T Cells, Salivary Gland, Bone, Thyroid, Lung

Publications for Keratoconjunctivitis

Articles related to Keratoconjunctivitis:

(show top 50) (show all 1439)
# Title Authors Year
1
Atopic keratoconjunctivitis: A diagnostic dilemma-a case report. ( 29668589 )
2018
2
Infectious keratoconjunctivitis in semi-domesticated Eurasian tundra reindeer (Rangifer tarandus tarandus): microbiological study of clinically affected and unaffected animals with special reference to cervid herpesvirus 2. ( 29338721 )
2018
3
Assessment of corneal and conjunctival metaplasia by impression cytology during the treatment of canine keratoconjunctivitis sicca. ( 29958527 )
2018
4
Recalcitrant Atopic Keratoconjunctivitis in Children: A Case Report and Literature Review. ( 29610174 )
2018
5
High Inflammatory Infiltrate Correlates With Poor Symptomatic Improvement After Surgical Treatment for Superior Limbic Keratoconjunctivitis. ( 29346129 )
2018
6
Adenovirus-related epidemic keratoconjunctivitis outbreak at a hospital-affiliated ophthalmology clinic. ( 29305276 )
2018
7
Corneal staining patterns in vernal keratoconjunctivitis: the new VKC-CLEK scoring scale. ( 29367201 )
2018
8
Epidemic Keratoconjunctivitis: (Superficial Punctate Keratitis, Keratitis Subepithelialis, Keratitis Maculosa, Keratitis Nummularis) With a Review of the Literature and a Report of 125A Cases. ( 29793576 )
2018
9
Immunohistochemical evaluation of lymphocyte populations in the nictitans glands of normal dogs and dogs with keratoconjunctivitis sicca. ( 29445621 )
2018
10
Efficacy of HL036 versus Cyclosporine A in the Treatment of Naturally Occurring Canine Keratoconjunctivitis Sicca. ( 29634381 )
2018
11
Epidemic keratoconjunctivitis cases resulting from adenovirus type 8 and 54 detected at Fukuoka University Hospital between 2014 and 2015. ( 29709978 )
2018
12
Increased Lacrimal Fluid Level of HMGB1 in Vernal Keratoconjunctivitis. ( 29847189 )
2018
13
Autonomic reinnervation and functional regeneration in autologous transplanted submandibular glands in patients with severe keratoconjunctivitis sicca. ( 29695713 )
2018
14
Anterior segment optical coherence tomography of microsporidial keratoconjunctivitis. ( 29676317 )
2018
15
Determinants of Outcomes of Adenoviral Keratoconjunctivitis. ( 29602567 )
2018
16
Re: Topical Tacrolimus for Corneal Subepithelial Infiltrates Secondary to Adenoviral Keratoconjunctivitis. ( 29664748 )
2018
17
Topical Tacrolimus 0.03% for Maintenance Therapy in Steroid-Dependent, Recurrent Phlyctenular Keratoconjunctivitis. ( 29309358 )
2018
18
Clinical Severity Classification using Automated Conjunctival Hyperemia Analysis Software in Patients with Superior Limbic Keratoconjunctivitis. ( 29336627 )
2018
19
Vernal keratoconjunctivitis in human immunodeficiency virus - The possible role of T-helper 1-T-helper 2 shift. ( 29941754 )
2018
20
Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast. ( 29958030 )
2018
21
SjAPgren-Like Lacrimal Keratoconjunctivitis in Germ-Free Mice. ( 29438346 )
2018
22
Vernal keratoconjunctivitis. ( 29391772 )
2018
23
Outcomes and Rationale of Excision and Mucous Membrane Grafting in Palpebral Vernal Keratoconjunctivitis. ( 29040121 )
2018
24
Recombinant type Human mastadenovirus D85 associated with epidemic keratoconjunctivitis since 2015 in Japan. ( 29396992 )
2018
25
Nuclear parameters and chromatin remodeling in epithelial cells and lymphocytes from the palpebral conjunctiva of dogs with keratoconjunctivitis sicca. ( 29493861 )
2018
26
Investigation of the efficacy of alcohol-based solutions on adenovirus serotypes 8, 19 and 37, the common cause of epidemic keratoconjunctivitis, after an adenovirus outbreak occurred in the hospital. ( 29792970 )
2018
27
Molecular typing and whole genome next generation sequencing of human adenovirus 8 strains recovered from four 2012 outbreaks of keratoconjunctivitis in New York State. ( 29750363 )
2018
28
Optimising tear replacement rheology in canine keratoconjunctivitis sicca. ( 29303147 )
2018
29
Clinical trials with multiple endpoints can establish a correlation, but not (yet) causality, between dietary supplementation with omega-3 fatty acids and keratoconjunctivitis sicca. ( 29781353 )
2018
30
Clinical and virological analysis of epidemic keratoconjunctivitis caused by adenovirus type 54 in a regional ophthalmic clinic in Kyushu, Japan. ( 29593376 )
2018
31
Microvascular Submandibular Gland Transplantation for Severe Keratoconjunctivitis Sicca: A Single-Institution Experience of 56 Cases. ( 29864431 )
2018
32
Comparative Evaluation of Tacrolimus Versus Interferon Alpha-2b Eye Drops in the Treatment of Vernal Keratoconjunctivitis: A Randomized, Double-Masked Study. ( 29040120 )
2018
33
Quality of life and clinical characterization of patients with vernal keratoconjunctivitis in a pediatric population in Colombia. ( 29338965 )
2018
34
Comparative study of 0.1% hyaluronic acid versus 0.5% carboxymethylcellulose in patients with dry eye associated with moderate keratitis or keratoconjunctivitis. ( 29928109 )
2018
35
Simple methods to optimize the success in microsurgical submandibular gland transplantation for the treatment of patients with keratoconjunctivitis. ( 29451330 )
2018
36
Rheumatoid factor isotype and Ro epitope distribution in primary SjAPgren syndrome and rheumatoid arthritis with keratoconjunctivitis sicca. ( 29936570 )
2018
37
Use of clinical vignette questionnaires to investigate the variation in management of keratoconjunctivitis sicca and acute glaucoma in dogs. ( 29275324 )
2018
38
Immunopathological Features of Severe Chronic Atopic Keratoconjunctivitis and Effects of Topical Cyclosporine Treatment. ( 30189151 )
2018
39
Transcriptome profiling of refractory atopic keratoconjunctivitis by RNA sequencing. ( 30471305 )
2018
40
Management of advanced ocular surface disease in patients with severe atopic keratoconjunctivitis. ( 30528292 )
2018
41
Case of phenylephrine hydrochloride-induced periorbital contact dermatitis with fulminant keratoconjunctivitis causing pseudomembrane formation. ( 28983944 )
2018
42
Efficacy of Trabodenoson in a Mouse Keratoconjunctivitis Sicca (KCS) Model for Dry-Eye Syndrome. ( 30025146 )
2018
43
Intravitreal anti-VEGF treatment for retinopathy of prematurity in infants with active adenoviral keratoconjunctivitis. ( 28393562 )
2018
44
Toxic Keratoconjunctivitis. ( 28445208 )
2018
45
TH17 cells mediate inflammation in a novel model of spontaneous experimental autoimmune lacrimal keratoconjunctivitis with neural damage. ( 28958903 )
2018
46
Comparison of the efficacy of 0.03% tacrolimus eye drops diluted in olive oil and linseed oil for the treatment of keratoconjunctivitis sicca in dogs. ( 29995121 )
2018
47
Infectious keratoconjunctivitis in free-ranging mule deer in Wyoming: a retrospective study and identification of a novel alphaherpesvirus. ( 30032722 )
2018
48
Pathogenesis and management of adenoviral keratoconjunctivitis. ( 30046247 )
2018
49
Outbreak of Microsporidial Keratoconjunctivitis Associated With Water Contamination in Swimming Pools in Taiwan. ( 30055152 )
2018
50
Punctate epithelial keratoconjunctivitis: A microsporidial infestation. ( 30127158 )
2018

Variations for Keratoconjunctivitis

Expression for Keratoconjunctivitis

Search GEO for disease gene expression data for Keratoconjunctivitis.

Pathways for Keratoconjunctivitis

Pathways related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 AOC1 CCL11 CD46 CXCL8 ICAM1 IFNG
2
Show member pathways
13.87 CCL11 CCL17 CXCL8 IL13 IL2 IL3
3
Show member pathways
13.73 CCL11 CCL17 CXCL8 IFNG IL13 IL2
4
Show member pathways
13.58 CCL11 CCL17 CXCL8 ICAM1 IFNG IL13
5
Show member pathways
13.46 CCL11 CCL17 CXCL8 IL13 IL2 IL3
6
Show member pathways
13.45 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
7
Show member pathways
13.38 CCL11 CCL17 CXCL8 IL13 IL2 IL3
8
Show member pathways
12.99 CXCL8 IFNG IL2 TLR9 TNF
9
Show member pathways
12.97 IL2 IL3 IL4 NGF TNF
10 12.92 CXCL8 IFNG IL13 IL2 IL3 IL4
11
Show member pathways
12.87 CD46 CXCL8 ICAM1 IFNG IL13 IL2
12
Show member pathways
12.8 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
13
Show member pathways
12.73 IL2 IL3 NGF TLR9 TNF
14 12.7 CD46 IFNG IL2 IL3 IL4 TLR9
15
Show member pathways
12.68 IFNG IL13 IL2 IL4 IL5 TNF
16
Show member pathways
12.63 IL13 IL3 IL4 IL5 TNF
17
Show member pathways
12.62 ICAM1 IFNG IL2 IL3 IL4 TNF
18
Show member pathways
12.5 IFNG IL13 IL2 IL3 IL4 IL5
19
Show member pathways
12.49 IFNG IL2 IL4 IL5 TNF
20
Show member pathways
12.43 CCL11 CCL17 CXCL8 IFNG IL13 IL4
21
Show member pathways
12.41 ICAM1 IFNG IL2 IL4 TNF
22
Show member pathways
12.33 CCL11 CXCL8 IFNG IL4 TLR9 TNF
23
Show member pathways
12.32 CXCL8 IFNG IL13 IL2 IL3 IL4
24
Show member pathways
12.25 CCL17 IL2 TLR9 TNF
25
Show member pathways
12.22 CCL11 CCL17 CXCL8 ICAM1 TLR9
26 12.22 CXCL8 IL13 NGF TNF
27 12.15 CXCL8 ICAM1 IFNG IL2 IL4 TNF
28 12.13 IFNG IL2 IL3 IL4 IL5 TNF
29 12.12 CCL11 CXCL8 ICAM1 IL13 IL4 TNF
30
Show member pathways
12.11 IFNG IL2 TLR9 TNF
31
Show member pathways
12.1 IFNG IL13 IL4 TNF
32
Show member pathways
12.09 IL13 IL2 IL5 TLR9
33
Show member pathways
11.97 CCL11 CCL17 CXCL8
34 11.97 IL3 IL4 IL5 TNF
35
Show member pathways
11.96 IFNG IL2 IL4
36 11.94 CXCL8 ICAM1 IFNG TNF
37 11.93 CXCL8 IFNG IL3
38 11.93 IFNG IL13 IL2 IL4 IL5 TNF
39 11.9 CXCL8 ICAM1 TNF
40 11.89 CXCL8 ICAM1 IFNG IL13 IL2 IL4
41 11.88 CXCL8 IFNG TNF
42 11.88 CXCL8 ICAM1 TNF
43 11.86 IFNG IL2 IL3
44 11.85 IFNG IL2 TLR9 TNF
45
Show member pathways
11.83 CXCL8 ICAM1 IFNG IL2 TNF
46
Show member pathways
11.83 CXCL8 IFNG IL2 IL3 IL4 IL5
47 11.79 CCL11 CXCL8 IL13 IL4 IL5 TNF
48 11.77 CCL11 CCL17 IL4 IL5
49 11.76 CCL11 CCL17 IFNG IL13 IL2 IL4
50
Show member pathways
11.71 CCL11 CCL17 CXCL8 ICAM1 IFNG IL13

GO Terms for Keratoconjunctivitis

Cellular components related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 AOC1 CCL11 CCL17 CXCL8 IFNG IL13
2 intracellular GO:0005622 9.7 CCL11 CXCL8 IFNG IL2 IL3 IL5
3 extracellular space GO:0005615 9.47 AOC1 CCL11 CCL17 CXCL8 ICAM1 IFNG

Biological processes related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.95 CD46 IFNG IL13 IL4 NGF TLR9
2 inflammatory response GO:0006954 9.91 CCL11 CCL17 CXCL8 IL13 IL5 TLR9
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.89 CCL11 CCL17 ICAM1 TNF
4 MAPK cascade GO:0000165 9.87 IL2 IL3 IL5 TNF
5 response to ethanol GO:0045471 9.84 ICAM1 IL13 IL2
6 response to virus GO:0009615 9.83 CCL11 IFNG TNF
7 cellular response to interferon-gamma GO:0071346 9.82 CCL11 CCL17 ICAM1
8 cytokine-mediated signaling pathway GO:0019221 9.81 CCL11 CXCL8 ICAM1 IL13 IL2 IL3
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.8 ICAM1 IL3 IL5
10 neutrophil chemotaxis GO:0030593 9.79 CCL11 CCL17 CXCL8
11 cellular response to tumor necrosis factor GO:0071356 9.78 CCL11 CCL17 CXCL8 ICAM1
12 positive regulation of inflammatory response GO:0050729 9.77 IL2 TLR9 TNF
13 chemokine-mediated signaling pathway GO:0070098 9.76 CCL11 CCL17 CXCL8
14 positive regulation of T cell proliferation GO:0042102 9.73 CD46 IL2 IL4
15 cellular response to interleukin-1 GO:0071347 9.73 CCL11 CCL17 CXCL8 ICAM1
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.72 IFNG IL13 IL2 IL3 IL4
17 positive regulation of nitric oxide biosynthetic process GO:0045429 9.71 ICAM1 IFNG TNF
18 immune response GO:0006955 9.7 CCL11 CCL17 CXCL8 IFNG IL13 IL2
19 embryonic digestive tract development GO:0048566 9.67 CXCL8 TNF
20 negative regulation of endothelial cell apoptotic process GO:2000352 9.67 ICAM1 IL13 IL4
21 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.66 IFNG TNF
22 regulation of regulatory T cell differentiation GO:0045589 9.65 IFNG IL2
23 positive regulation of B cell proliferation GO:0030890 9.65 IL13 IL2 IL4 IL5 TLR9
24 positive regulation of immunoglobulin secretion GO:0051024 9.64 IL2 IL5
25 positive regulation of podosome assembly GO:0071803 9.64 IL5 TNF
26 positive regulation of regulatory T cell differentiation GO:0045591 9.63 CD46 IL2
27 response to molecule of bacterial origin GO:0002237 9.63 CXCL8 TLR9
28 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.61 TLR9 TNF
29 positive regulation of isotype switching to IgG isotypes GO:0048304 9.61 IL2 IL4
30 positive regulation of immunoglobulin production GO:0002639 9.58 IL13 TLR9
31 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.55 ICAM1 TNF
32 negative regulation of complement-dependent cytotoxicity GO:1903660 9.52 IL13 IL4
33 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.51 IFNG TNF
34 positive regulation of vitamin D biosynthetic process GO:0060557 9.46 IFNG TNF
35 regulation of signaling receptor activity GO:0010469 9.36 CCL11 CCL17 CXCL8 IFNG IL13 IL2

Molecular functions related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.43 IL2 IL3 IL5
2 growth factor activity GO:0008083 9.35 IL2 IL3 IL4 IL5 NGF
3 chemokine activity GO:0008009 9.33 CCL11 CCL17 CXCL8
4 cytokine activity GO:0005125 9.32 CCL11 CCL17 CXCL8 IFNG IL13 IL2

Sources for Keratoconjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....